NCCN Guidelines® on CD30 testing in lymphoma*
The NCCN Guidelines recommend CD30 testing for the differential diagnosis of Hodgkin and certain non-Hodgkin lymphomas.1,2
CD30 testing is recommended for the diagnosis of the following lymphomas:
- Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)–positive2
- ALCL, ALK-negative2
- Angioimmunoblastic T-cell lymphoma (AITL)2
- Enteropathy-associated T-cell lymphoma (EATL)2
- Hodgkin lymphoma1
- Mycosis fungoides/Sézary syndrome when large cell transformation is observed2
- Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)2
CD30 testing is useful under certain circumstances in the following lymphomas:
- Diffuse large B-cell lymphoma (DLBCL)2
- Mycosis fungoides/Sézary syndrome2
- Post-transplant lymphoproliferative disorders2
Antibody panels directed toward multiple antigens can aid diagnostic decisions by complementing morphologic findings and clinical characteristics.3 For example, although Hodgkin lymphoma cells are characterized by the distinct morphology of the Reed-Sternberg cell, the NCCN Guidelines recommend a panel of antigens, including CD30, in the diagnosis of Hodgkin lymphoma.1
Sample Hodgkin lymphoma IHC panel3
|Antigen||Reactivity in normal lymphoid tissues||Findings in RS cells in cHL|
|PAX 5||B cells||Most cases (≈90%) positive|
|CD20||B cells||Sometimes positive in a subset|
|CD3||T cells, NK cells||Negative|
|CD15||Granulocytes, some histiocytes, epithelial cells and carcinomas, CMV-infected cells||Most cases (≈85%) positive|
|CD30||Activated lymphoid cells||Positive|
|RS = Reed-Sternberg; cHL = classical Hodgkin lymphoma; CMV = cytomegalovirus; LCA = leukocyte common antigen|
CD30 IHC complements morphologic findings in classical Hodgkin lymphoma
All images were provided by Dr. Mariusz Wasik, Professor of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Hodgkin Lymphoma (Version 2.2013). © 2013 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed September 24, 2013.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Hodgkin’s Lymphomas (Version 2.2013). © 2013 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed September 24, 2013.
- Wasik MA, Jimenez GS, Weisenburger DD. Targeting CD30 in malignant tissues: challenges in detection and clinical applications. Pathobiology. 2013;80(5):252-258.
NCCN recommends CD30
The NCCN Guidelines* recommend CD30 testing for the differential diagnosis of Hodgkin and certain non-Hodgkin lymphomas...
The clinical relevance of CD30
Appropriate management of patients with lymphoma depends on an accurate diagnosis...
CD30 in NHL prognosis
The definitive role of prevalence and intensity of CD30 in prognosis is evolving...
Study finds CD30 in 17 cancers
In a study of over 1,500 patients with nonlymphomatous malignancies, 17 different diagnoses were associated...
CD30 in Burkitt lymphoma
25% of Burkitt lymphoma cases express CD30. The endemic variant, African Burkitt lymphoma...
CD30 and overall survival in PTCL‑NOS
A recent study found that CD30 expression is an adverse predictor of survival in peripheral T-cell lymphoma...
CD30 screening in germ cell tumors
CD30 is strongly expressed in more than 95% of embryonal carcinomas, while other germ cell tumors lack CD30...
*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Hodgkin’s Lymphomas V.2.2013 and Hodgkin Lymphoma V.2.2013. © National Comprehensive Cancer Network, Inc 2013. All rights reserved. Accessed September 24, 2013. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.